A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
#1PRI RANKED
Most Cited Paper
in Liver Disease Diagnosis and Treatment
18 Months Post-Publication
Class of 2026
“A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
resmetirom · Steatohepatitis · Steatohepatitis · Liver fibrosis · thyroid hormone receptor beta-selective agonist · Steatohepatitis resolution · Liver fibrosis improvement · NAFLD Activity Score · F1B fibrosis · Fibrosis stage F2 · Fibrosis stage F3 · Biopsy-confirmed steatohepatitis · LDL cholesterol · 80 mg resmetirom · 100 mg resmetirom · liver-directed therapy · MAESTRO-NASH trial
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026. Accessed 2026-07-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459